Happy Thursday! This edition of the Patient Worthy Editor's Choice is coming to you a little early this week. If you're reading from the United States, we hope you enjoy…
According to Medical Xpress, a new gene therapy has been studied for the treatment of Duchenne muscular dystrophy. This treatment, SRP-9001, has been shown to deliver micro-dystrophin and improve functional…
According to a recent article in Parkinson’s News Today, results of an extension study confirm that FDA approved Nuplazid (pimavanserin) reduces the severity of delusions and hallucinations in Parkinson’s disease…
Currently, up to 5% of American citizens have nonalcoholic steatohepatitis (NASH), a liver disease resulting in damage and inflammation. But there's no approved treatments, presenting an unmet need in…
Acadia Pharmaceuticals recently released the results of their Phase 3 trial of Nuplazid, a treatment for the psychosis that Parkinson's disease patients experience. This medication has been approved since 2016,…
Ultomiris, a product of Alexion Pharmaceuticals, has recently been studied in a Phase 3 clinical trial. This study was intended to ultomiris' effect on life-threatening complications of atypical hemolytic uremic…
-150x150.jpg)
Neurotrope is launching a long term Phase 2 trial of Bryostatin-1, which is a treatment for Alzheimer's disease. The National Institutes of Health (NIH) will be joining this study, giving…
As reported in Med Gadget, Medtech company ’11 Health’ has made virtual healthcare affordable this quarantine season, providing patients with severe chronic digestive disorders 12 weeks of free access on their…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
